Drug Approval | August 11, 2024
Zydus receives final approval from USFDA for Valbenazine Capsules
Valbenazine Capsules had annual sales of US $1,993.6 mn in the United States (IQVIA MAT June 2024)
Valbenazine Capsules had annual sales of US $1,993.6 mn in the United States (IQVIA MAT June 2024)
Diroximel Fumarate Delayed-Release Capsules is indicated for the treatment of relapsing forms of multiple sclerosis
Doxycycline capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
The Unit currently caters to emerging markets of Latin America and Africa with a variety of dosage forms
ORACEA is a trademark of Galderma Holdings, S.A.
Colchicine Capsules are indicated for prophylaxis of gout flares in adult
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ II, India
The product will be launched in March 2024
Subscribe To Our Newsletter & Stay Updated
